Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor — STRADA  

Solitary Fibrous Tumors Clinical Trial

Official title: Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients

Status Active, not recruiting

Clinical Trial Summary

Phase II randomized study for the comparison of trabectedin versus doxorubicin plus dacarbazine in patients with advanced solitary fibrous tumor

Clinical Trial Description

Patients with solitary fibrous tumor will be randomized to receive 6 cycles of trabectedin or doxorubicin plus dacarbazine.

In case of progression or unacceptable toxicity while under the experimental treatment prior to the completion of the 6 cycles, the patients will be offered to cross to the other arm (trabectedin arm to doxorubicin plus dacarbazine arm and vice versa). ;

Related Conditions & MeSH terms

• Hemangiopericytoma
• Solitary Fibrous Tumors

• NCT number: NCT03023124
• Study type: Interventional
• Source: Italian Sarcoma Group
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: March 4, 2018
• Completion date: December 2024